Developing Memory Reconsolidation Blockers as Novel PTSD Treatments
Abstract
We have successfully implemented the proposed animal experiments at each study site. Key accomplishments to date are the demonstration that the antiprogesterone and glucocorticoid receptor antagonist mifepristone, and the protein-synthesis inhibitor rapamycin, when administered systemically reduce reconsolidation of a cue-conditioned fear response in rats. We have also made substantial progress toward implementing the first two studies we will undertake in human subjects. First, a double-blind, randomized, placebo-controlled pilot trial of six sessions of post-reactivation propranolol for the treatment of PTSD is in the final stages of obtaining DOD IRB approval, after which recruitment will begin. Second, we have formulated the design of a pilot study of single-session, post-reactivation mifepristone's ability to reduce psychophysiologic responses during traumatic imagery in trauma-exposed human subjects. We have succeeded in obtaining an investigational new drug (IND) approval from the FDA for this post-marketing application of mifepristone. We are now in the final stages of obtaining approval from the local institutional review board (IRB). Following that, we will prepare a DOD IRB submission.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2009
- Accession Number
- ADA515115
Entities
People
- Roger K. Pitman
Organizations
- Massachusetts General Hospital